GlassScriptPhysician profile
Junaid Ahmed
NPI 1639171630
$564.78
in general payments reported to CMS, 2019-2025
13 companies · $60.69 in 2025
The $60.69 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2021: $102 · 2022: $16.34 · 2023: $180 · 2024: $79.10 · 2025: $60.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $114.45 | 2019-2024 | Parsabiv, Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $85.13 | 2023-2025 | |
| Abbott Laboratories | $80.43 | 2023 | Cardiomems |
| Novo Nordisk INC | $47.27 | 2021-2023 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $38.23 | 2019-2021 | |
| Glaxosmithkline, LLC. | $34.32 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $30.03 | 2024 | Terlivaz |
| Astrazeneca Pharmaceuticals LP | $25.77 | 2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $24.29 | 2021 | |
| Akebia Therapeutics INC | $23.78 | 2019 | |
| Aurinia Pharma U.S., INC. | $23.03 | 2023 | Lupkynis |
| Horizon Therapeutics Plc | $21.34 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $16.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junaid Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.